The formation of reactive oxygen species (ROS) and the change of the intracellular pH (pH i ) are common phenomena during apoptosis. How they are interconnected, however, is poorly understood. Here we show that numerous anticancer drugs and cytokines such as Fas ligand and tumour necrosis factor a provoke intracellular acidification and cause the formation of mitochondrial ROS. In parallel, we found that the succinate:ubiquinone oxidoreductase (SQR) activity of the mitochondrial respiratory complex II is specifically impaired without affecting the second enzymatic activity of this complex as a succinate dehydrogenase (SDH). Only in this configuration is complex II an apoptosis mediator and generates superoxides for cell death. This is achieved by the pH i decline that leads to the specific dissociation of the SDHA/SDHB subunits, which encompass the SDH activity, from the membrane-bound components of complex II that are required for the SQR activity.
Intracellular acidification is, besides cell shrinkage, membrane blebbing, DNA fragmentation, and phosphatidylserine exposure, a commonly described phenomenon during the apoptotic process. It constitutes an early event during apoptosis and precedes mitochondrial dysfunction. 1 A wide variety of apoptosis signals can cause this pH drop, typically in the range of 0.3-0.4 pH units, such as UV-irradiation, death receptor triggering, growth factor deprivation, and anticancer compounds, and also genes such as p53 and Bax activation. [1] [2] [3] This can be accomplished by modulating the activity of plasma membrane transporters such as the alkalinising transporter Na þ /H þ exchanger 1 (NHE1), which seems to be inhibited during apoptosis. 1 Although it has been suggested that the pH change can contribute to caspase activation, 4 exactly how pH changes are linked to more downstream signals during apoptosis induction is only poorly understood.
Reactive oxygen species (ROS) are long known as general mediators of apoptosis. Mitochondria are regarded as the main, but not the sole source for ROS. 5 Although complex I and III have long been recognised as supplying ROS for apoptosis, 6 in recent years complex II has also been established as an efficient producer of ROS, particularly superoxides, for apoptosis induction. 7 Sensitive detection methods indicated that it can surpass even complex III for ROS formation. 8 Structural studies likewise indicate that complex II can produce ROS. 9 However, the exact mechanism by which complex II generates ROS in response to apoptosis signals remains unknown.
With only four subunits, complex II is the smallest protein complex of the mitochondrial respiratory chain and the only complex to be fully encoded by nuclear DNA. 10 The SDHC and SDHD proteins form the membrane-anchoring components, which associate with two subunits facing the mitochondrial matrix: SDHB, an Fe-S protein, and SDHA, a FAD-containing protein 11 (Supplementary Figure 1a) . Complex II is also a component of the Krebs cycle with its succinate dehydrogenase (SDH) activity oxidising the metabolite succinate to fumarate. The electrons generated in this reaction are then channelled in a not completely understood pathway within complex II to ubiquinone, which is reduced to ubiquinol by the succinate:ubiquinone oxidoreductase (SQR) activity of complex II. Finally, the reduction equivalents are shuttled to complex III in the respiratory chain. 12 Here we demonstrate that various compounds and cytokines cause an intracellular pH (pH i ) acidification and ROS formation during apoptosis. We found that these prominent features of apoptosis are linked by the specific inhibition of complex II.
Results
Early intracellular acidification and ROS formation during apoptosis. We set up a suitable cellular system to study the early events of apoptosis signalling. At 7 h after addition of various anticancer agents, HeLa cells showed no signs of apoptosis induction such as nuclear DNA degradation ( Figure 1a ) or phenotypic changes (not shown). However, after 24 h, these drugs at the concentrations used caused apoptosis as evidenced by an increase of the sub-G1 cell population. The Fas ligand (FasL) and tumour necrosis factor Figure 1 pH change during apoptosis. (a) Apoptosis induction by anticancer drugs and cytokines. HeLa cells were treated with the indicated drugs for 7 and 24 h or exposed to FasL or TNF-a for 16 and 36 h (see Materials and Methods). After treatment, apoptotic cells were quantified by flow cytometry using PI staining of the sub-G1 population. *Po0.05 compared with the related control. (b) The pro-apoptotic agents lead to cytosolic acidification. HeLa cells were treated for 7 h with the indicated drugs or cytokines. EIPA (20 mM), an inhibitor of NHE1, was used as a positive control for cytosolic acidification. Cells were collected and incubated with the pH-sensitive fluorescent probe carboxy-SNARF-1. pH-related fluorescence ratios were analysed by flow cytometry and converted into pH values. Results are normalised to pH i in untreated cells and expressed as DpH i values. *Po0.05 compared with pH i in untreated cells. (c) Inhibition of the NHE1 transporter by EIPA potentiates the apoptosis induced by the pro-apoptotic agents. HeLa cells were treated for 26 h with the anticancer drugs or cytokines in the presence or absence of 20 mM EIPA. Apoptosis was measured as in (a). # Po0.05. (d) Overexpression of NHE1 reduces cell death induced by the various pro-apoptotic signals and inhibits cytosolic acidification. HeLa cells were transfected either with pcDNA3 or with a NHE1 expression plasmid. After 48 h, when the NHE1 mRNA level was upregulated (see inset), the cells were treated with the anticancer drugs or cytokines. Changes in pH i (left panel) were quantified by flow cytometry after a 7-h treatment, as in (b). Apoptosis (right panel) was measured after 26 h as in (a). Results are shown after subtraction of the pcDNA3-associated apoptosis background. # Po0.05. (e) The different pro-apoptotic agents responsible for complex II inhibition lead to mitochondrial matrix acidification. HeLa cells were co-transfected for 24 h with a mt-EYFP plasmid, sensitive to pH M changes, and with a mt-dsRed plasmid (insensitive). Cells were treated for 7 h with the different anticancer drugs or cytokines. CCCP (10 mM for 20 min), a mitochondrial protonophore, was used as a positive control for mitochondrial matrix acidification. pH M -related fluorescence ratios were analysed by flow cytometry (see Materials and Methods) and converted into pH M values. *Po0.05 compared with control a (TNF-a) cytokines exerted a delayed effect on apoptosis with only a marginal sub-G1 cell population at 16 h but a substantial apoptosis after 36 h (Figure 1a ). An additional assay for caspase-3 activity and poly (ADP-ribose) polymerase (PARP) cleavage confirmed apoptosis induction (Supplementary Figure 2) . When we measured pH i 8 h after treatment and before apoptosis, we observed a pH i decrease with all pro-apoptotic signals used (Figure 1b) . EIPA, an inhibitor of the alkalinising transporter NHE1 used as an acidification control, markedly potentiated apoptosis in co-treatments with all agents (Figure 1c) . Conversely, when we transiently overexpressed NHE1, we prevented acidification following drug and cytokine treatment and strongly reduced apoptosis (Figure 1d ). We were also able to show that the mitochondrial matrix acidified in parallel with the cytosolic pH i drop (Figure 1e) .
We then studied whether ROS could be causative for apoptosis triggered by the compounds shown in Figure 1 . Using the dihydroethidium (DHE) probe (Supplementary Figure 3a) and the mitochondria-specific probe MitoSOX (Figure 2a) , we confirmed that all these agents could elicit the formation of ROS at 8 or 16 h after their application. Different efficiencies in ROS generation were noticed, probably because some compounds can induce ROS formation through additional pathways. 13, 14 Moreover, we showed that pre-treatment with PEG catalase, a cell-permeable form of catalase, 15 could reduce their potential to induce apoptosis, underlining the fundamental role of ROS in the apoptotic cascade ( Figure 2b ). We also demonstrated that acidification impairment through NHE1 overexpression markedly reduced drug-induced mitochondrial ROS production (Supplementary Figure 3b) . Finally, as our previous work showed a role of complex II in ROS production and apoptosis, 16 we used the SDH inhibitor malonate and observed a reduction of apoptosis induced by all compounds, suggesting that complex II-dependent ROS accumulation is at least partly responsible for apoptosis induction (Figure 2c ).
Specific inhibition of complex II for apoptosis induction. On the basis of our previous work 16 and the results with the complex II inhibitor malonate (Figure 2c) , we investigated the effects of the apoptosis inducers on complex II in more detail with two assays classically used for the enzymatic activities of complex II (described in Supplementary  Figure 1b and c). We found that at 7 h (anticancer drugs) and 16 h (cytokines) after treatment, the SDH activity of complex II was not compromised, whereas its SQR activity was inhibited by B20% (Figure 3a) . Thus, we hypothesised that complex II contributes to apoptosis induction only when the SQR activity is inhibited while the SDH activity is still fully functioning, creating an uncoupling phenomenon at the complex II level. This model, however, seemed to be in conflict with the discovery in cancer cells with inactivating mutations in the complex II membrane anchoring subunits SDHC and SDHD 17 that appear to lead to apoptosis resistance and tumour formation rather than cell death induction. Consequently, we set up experiments to test the consequences on the SQR and SDH activity and on apoptosis induction upon specific disruption of the various complex II subunits by shRNA constructs. Figure 3b shows that the mRNAs of all targeted complex II components were reduced after 72 h, whereas the mRNA expression levels of their associated subunits remained unaffected. We also confirmed the downregulation of the respective proteins by western blot (Figure 3c ). Our expectation was that we detect apoptosis when the membrane-bound subunits are downregulated but not then the peripheral components of complex II were targeted. However, we did not observe any apoptosis induction following a 72-h transfection with these shRNA (Figure 3d ). When we measured the enzymatic activities of complex II, we found that both SDH and SQR activity were markedly and equally downregulated when SDHA and SDHB were targeted, and also when SDHC and SDHD were inhibited (Figure 3e ). This seems to be due to a major impairment of the whole complex assembly in the mitochondria (Supplementary Figure 4) . When we targeted SDHC, SDHD, or SDHB, all the other subunits were likewise reduced in the mitochondria, except SDHA. Hence, inactivation of complex II subunits as observed in cancer cells could impair the whole complex II and, consequently, the association of an active SDH activity with an inhibited SQR function is not possible, rendering complex II incapable of apoptosis induction and promoting tumourigenesis. To further prove that the observed effects depend on complex II, we made use of SDHCÀ/À and wildtype (wt) SDHC-reconstituted B9 cells. 18, 19 Stable clone 4 expressed the SDHC transgene at a level comparable to that of the parental wt B1 cells (Supplementary Figure 5a) . We found that by expressing wt SDHC (clone 4) we could restore both SDH and SQR activity to a similar level than in parental B1 cells (Supplementary Figure 5b) . Importantly, complex IIreconstituted cells were also re-sensitised to apoptosis induction by anticancer drugs (Figure 3f ). Thus, on the basis of all these findings, we hypothesised that complex II contributes to apoptosis induction when functional complex II aggregates become inactive for the SQR activity, whereas the SDH function is still fully effective. Although this cannot happen in tumour cells with complex II-inactivating mutations, in wt cells it creates uncoupling at the complex II level leading to ROS production and subsequent apoptosis.
In order to assess the cellular consequences of a selective and partial SQR inhibition as observed in Figure 3a , we turned to complex II inhibitors, which facilitate a specific, concentration-dependent attenuation of complex II activities: 3-nitroproprionic acid (3NP), a succinate analogue, binds to the active site of SDHA and inhibits complex II irreversibly. 11 Thenoyltrifluoroacetate (TTFA) inhibits a later step of the electron flow as it binds to the ubiquinone docking sites and abrogates the transfer of electrons to this molecule. 11 Apoptosis assays revealed that 3NP did not elicit an apoptotic effect at the concentrations tested, whereas TTFA caused a time-and dose-dependent increase of apoptosis ( Figure 4a ). In line with the known specificity of these compounds, we have observed an inhibition of both, SQR and SDH activity, with 3NP, while TTFA reduced only the SQR activity, before apoptosis ( Figure 4b , upper panel). Of note, 0.5 mM TTFA, which caused apoptosis (Figure 4a ), diminished the SQR activity by 20%, a reduction also observed with the pro-apoptotic compounds ( Figure 3a ). An in vitro dose-escalation experiment on isolated mitochondria confirmed the concentration-dependent SQR inhibition by TTFA (Figure 4b , lower panel).
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Apoptosis signals are mediated through complex II-dependent ROS production. On the basis of the above experiments, which highlight the importance of an inhibited SQR activity without SDH impairment for apoptosis induction, we speculated that if electrons provided by succinate oxidation could not efficiently be transferred to ubiquinone, they would leak out from complex II, generate ROS, and eventually trigger apoptosis. Using DHE, we found that after an 8-h treatment and before apoptosis, ROS were rapidly generated by TTFA in a dose-dependent manner. The 3NP, on the contrary, did not show ROS production at all doses used at this early time point (Figure 5a ). With
MitoSOX, we also demonstrated that TTFA-induced ROS had a mitochondrial origin (Supplementary Figure 3c) . Pretreatment with antioxidant enzymes (PEG-catalase and superoxide dismutase (SOD)) or ROS quenchers (Trolox) could reduce TTFA-induced ROS production and likewise apoptosis (Figure 5b and c). In addition, the transfection of plasmids coding for catalase and for mitochondrial manganese SOD (MnSOD) also potently diminished TTFAinduced apoptosis (Figure 5d ). These results suggested that complex II, if specifically inhibited, can function as a source for ROS and apoptosis induction. ROS are known to also cause the passive cell death of necrosis. 20 Hence, to examine whether the observed cell death was apoptosis, we analysed specific features of apoptosis, such as caspase-3 activity and PARP cleavage, and found that both of them increased upon TTFA treatment (Supplementary Figure 2) . We also performed propidium iodide (PI) and annexin V (AV) double staining and found that necrotic PI þ /AVÀ cells only marginally accumulated upon TTFA treatment (Supplementary Figure 6a ) in contrast to PIÀ/AV þ apoptotic cells. PI þ /AV þ double-stained necrotic or late-apoptotic cells significantly increased in response to TTFA. Nevertheless, the cell populations positive in sub-G1 (apoptotic) or 7-aminoactinomycin D (7-AAD) (necrotic and late apoptotic) assays could potently be reduced by zVAD-fmk, a pancaspase inhibitor ( Supplementary Figure 6b and c) . We hypothesised that, if the TTFA pro-apoptotic effects are due to specific inhibition of complex II at the SQR level, upstream inhibitors of complex II such as those of the Krebs cycle (fluoroacetate, fluorocitrate) or of the SDH activity (3NP, malonate), would also reduce TTFA-induced ROS formation and apoptosis. Figure 5e reveals that all the upstream Figure 7 , suggested that specific complex II inhibition contributed to pro-apoptotic ROS formation through electron leakage between the SDH activity, which is linked to the Krebs cycle, and the SQR activity, as part of the respiratory chain. Also, in contrast to pcDNA3-transfected cells, SDHCreconstituted B9 cells were again able to produce ROS and undergo apoptosis when treated with TTFA (Figure 5f ) confirming the specificity of our observed effects for complex II.
pH change leads to specific disintegration of complex II. We tested both complex II activities in the mitochondria kept in buffers with reduced pH in vitro, and observed a reduction in the SQR activity while the SDH activity remained unchanged (Figure 6a , left panel). Cytosolic acidification imposed on cells by EIPA also triggered a reduction of the SQR activity without affecting the SDH activity ( Figure 6a, right panel) . To explain at a molecular level the observed different enzymatic activities of complex II during apoptosis, we investigated the integrity of this protein aggregate. We separated mitochondrial proteins in a blue native gel after incubating these organelles in a phosphate buffer with normal or reduced pH. A western blot for SDHA revealed an additional band indicating the dissociation of the 100 kDa SDHA/B subcomplex, which is exposed to the mitochondrial matrix, from the integral membrane protein SDHC and SDHD (Figure 6b, left panel) . This partial complex II dissociation is correlated with the partial loss of the enzymatic activity of SQR. The emergence of the SDHA/B subcomplex was likewise apparent when intact HeLa cells were treated for 7 h with As 2 O 3 or doxorubicin and total protein extracts separated on a blue native gel (Figure 6b , right panel). The same dissociation pattern was also observed in human 293T cells (Supplementary Figure 8) . Moreover, inhibition of acidification by NHE1 overexpression in HeLa cells significantly reduced the partial dissociation of complex II after drug treatment (Figure 6c ). and apoptosis (c) in response to specific complex II inhibition. HeLa cells were pre-treated with superoxide dismutase (SOD, 4000 UI/ml), Trolox (100 mM) or PEG-catalase (1000 UI/ml), and exposed to 1 mM TTFA for 20 h. ROS were determined as in (a) and apoptosis was measured by flow cytometry using PI staining of the sub-G1 population. # Po0.05. Luciferase expression had no effect on apoptosis (Supplementary Figure 10) . (e) Effects of different SDH inhibitors (3NP, malonate), Krebs cycle inhibitors (fluorocitrate, fluoroacetate), or a Krebs cycle intermediate (succinate DBE) on apoptosis and ROS production induced by TTFA. HeLa cells were treated with 1 mM TTFA and the indicated compounds. As a control the inhibitors were used in their own. ROS and apoptosis were quantified as in (a) and (c), respectively. The mitochondria contain a number of master regulators for apoptosis. We have proposed that complex II of the respiratory chain constitutes such a mitochondrial factor for apoptosis control. In a previous study, we showed that defects in complex II rendered cells resistant to apoptosis induction by a wide array of pro-apoptotic signals. 16 Additional independent studies also implicate complex II as an important sensor that is used by various signals for apoptosis induction. SDHD downregulation by RNAi, for example, was shown to protect neuronal cells against apoptosis by NGF withdrawal. 21 Moreover, complex II inhibition by transfecting an SDHC mutant for the ubiquinone-binding site induced apoptosis. 7 In this study, we addressed why complex II constitutes a major target in pro-apoptotic signalling and the mechanism of this process. Our results show that various anticancer compounds and pro-apoptotic cytokines are able to inhibit complex II specifically at the SQR level, which is responsible for ubiquinone reduction and links complex II with the respiratory chain. At the same time, the upstream SDH activity, which is associated with succinate oxidation and hence with the Krebs cycle, is not impaired. We provide evidence that this is accomplished through intracellular acidification, concomitant with mitochondrial pH decrease. This pHi drop appeared to be a synchronic event in the whole HeLa cell population, as shown by the flow cytometry density blots depicted in Supplementary Figure 9 . As pHi decline is a general phenomenon during apoptosis, 1 it could explain the ubiquitous involvement of complex II in apoptosis induction. Accordingly, pH changes were previously found in connection with some of the compounds tested here, such as FasL, TNF-a, etoposide, cisplatin, or arsenic. 1, 2, [22] [23] [24] However, very few studies analysed the role of mitochondrial matrix pH (pH M ) during chemically induced apoptosis. Although one work described an early mitochondrial matrix alkanisation, 4 it appears that this transient phase is followed by a significant matrix acidification leading to apoptosis. 25 In our study, pH i acidification, associated with pH M drop, appears to be essential for specific SQR inhibition and subsequent apoptosis, as pH i modification by EIPA (acidifying compound) or NHE1 overexpression (acidification inhibition) can either potentiate or block cell death, respectively. Moreover, assays both in vitro (Figure 6a ) and in intact cells (Figures 3a with 1b and e) for complex II activities underline the specific sensitivity of the SQR function to acidification. These data suggest that complex II is an important sensor for pro-apoptotic signals through its pH sensitivity (schematised in Figure 7 ).
Our experiments with isolated mitochondria in buffers with different pH or recovered from cells treated with drugs indicated that complex II is unstable and can specifically dissociate. Blue native gel electrophoresis of complex II indicated that SDHA and SDHB, the two subunits exposed to the matrix and attached to the complex II-membrane anchors can be released from this complex (Figure 6b ). This is in agreement with earlier studies showing that their association can be broken by chaotrophic ions and treatments such as freeze-thawing. 26, 27 As the SDH activity is associated with SDHA/B this dissociation retains this enzymatic activity but abrogates the downstream SQR function, leading to the uncoupling between SDH and SQR activity (Figure 7) . ROS generation by respiratory chain complex II. Before apoptosis induction we observed a partial reduction of the total cellular complex II SQR activity (Figure 3a) . We believe that this is due to some of the complex II aggregates in the affected cells shutting down the SQR activity while maintaining the SDH activity (Figure 7b) . As a result of this specific complex II inhibition, the electron flux from the citrate cycle through complex II is altered in three ways (i) electrons cannot efficiently be transferred to the ubiquinone-binding sites; (ii) the electron flow is disrupted within the complex; and (iii) the electrons react with molecular oxygen to produce superoxide radicals, which eventually trigger apoptosis ( Figure 7 ). Of note, the DHE and MitoSOX probes used in this study have been described as relatively specific for superoxide detection, even though they may give an unspecific response for superoxides, 28 notably at the 488 nm excitation wavelength used for FACS application. However, we showed that the superoxide scavenger SOD can potently reduce (i) the DHE and MitoSOX signals induced upon complex II inhibition and (ii) the subsequent apoptosis (Figure 5b-d and Supplementary Figure 3d) , confirming that the complex II blockade generates superoxides. A block in various complexes of the respiratory chain has been shown to induce ROS formation and subsequent apoptosis, 5 particularly at the complex I and III level. 6 Interestingly, the cleavage of complex I subunits NDUFS1 or NDUFS3 by caspases 29 or granzyme A, 30 respectively, can lead to superoxides and apoptosis. Long considered a physiologically negligible site for ROS production, complex II has been recently described by us 16 and others to mediate intracellular signalling through superoxide generation in a number of scenarios, such as (i) mutations of the coenzyme Q (CoQ)-binding site of SDHC in Caenorhabditis elegans, 31 Escherichia coli,
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Saccharomyces cerevisiae, 32 and mammals; 7 (ii) mutation or destabilisation of SDHB; 33 and (iii) chemical inhibition of the succinate or CoQ-binding site. 34 Different sites for superoxide generation within complex II have been proposed depending on the cause of complex II inhibition, notably at the SDHC/D CoQ-binding site 32 or between the SDHA-embedded FAD group and a downstream obstruction. 33 Nevertheless, the precise molecular mechanisms of such a blockade were rarely explored. Some recent studies have evoked either a stabilisation of the ubisemiquinone radical 35 or a modification of the glutathionylation and the tyrosine nitration status of SDHA. 36 Our data demonstrate that another major cellular factor, pH i homoeostasis, can have an impact on complex II functions and facilitate ROS production.
Role of complex II in tumourigenesis. Mutations in the SDHB, C and D subunits that cripple complex II have been found in various cancers, particularly paragangliomas and phaeochromocytomas, 17 suggesting that this confers a selective growth advantage to cells and led to define its subunits as tumour suppressor proteins. 10 During the past 10 years, research exploring the biochemical causes of complex II inhibition and tumourigenesis found different metabolic pathways to be involved. First, in complex II-impaired cells, the SDH substrate succinate accumulates in the mitochondria, is transported into the cytosol, and inhibits HIF1a prolyl hydroxylase. This leads to HIF1a stabilisation and activation, 37 and finally to a pseudohypoxia tumor phenotype 38 and apoptosis inhibition. 21 A second pathway involves the generation of ROS in association with mutated or destabilised complex II 7, 33 leading to mtDNA damage 39 and likewise HIF1a activation. 33 Our results allow us to propose a third pathway that highlights the role of complex II as a major apoptosis regulator: Numerous pro-apoptotic signals target complex II and lead to (i) a specific inhibition of SQR activity without SDH impairment; (ii) uncoupling of these two enzymatic activities; (iii) superoxide production; and finally (iv) cell death induction. Our shRNA experiments (Figure 3b-e and Supplementary Figure 4) and data from SDHC-negative B9 cells (Figures 3f and 5f ) indicate that specific downregulation of complex II subunits inhibits the aggregation of the whole complex II in the mitochondria. This on its own does not elicit apoptosis (HeLa cells, Figure 3d ) and even leads to anticancer drug resistance (B9 cells, Figure 3f ). These findings are also supported by other independent studies showing that, in cancer patients with mutations in complex II subunits, the remaining components of this complex are either not present 40 or display a profoundly reduced complex II activity. 41 Hence, in tumours harbouring such altered genes, the combination of a partial SQR inhibition and a fully active SDH is not possible, as both activities are downregulated, therefore impairing the apoptotic process. We believe that this is the reason why these cells can survive the onset of such mutations and eventually form tumour cells. This model does not exclude that parallel processes, such as a hypoxia-like pathway through the stabilisation of the HIF1a transcription factor, 37 also contribute to tumorigenesis. Nevertheless, our findings can contribute to explain why components of complex II function as tumour suppressor genes.
In conclusion, our study brings together two common features of apoptosis in response to pro-apoptotic signals: pH i change and ROS formation. We found that they are interconnected by the specific inhibition of complex II of the respiratory chain, which is accomplished by the release of the SDHA/SDHB subunits from the whole complex.
Materials and Methods
Cell culture and treatments. Human HeLa cells and the SDHC-deficient B9 cells, derivatives from the Chinese hamster CCL16 parental cell line (B1 cells), 19 were cultivated as described. 16 The concentrations used for treatments are shown in Supplementary Table 1.
Chemicals. All the reagents are described in Supplementary Experimental Procedures.
ShRNA constructs. ShRNA against human SDHA/B/C/D were designed (Supplementary Table 2 ) and checked for specificity with the iRNAi software (http:// www.mekentosj.com/irnai/). Specific primers for SDHA/B/C/D as well as scrambled primers (of the SDHB sequence) as a negative control were synthesised and inserted into pSuper vector (Oligoengine, Seattle, WA, USA).
Transfections and plasmids. Cells were transfected with plasmid DNA either by Lipofectamine 2000 or Effectene in B9 (30% efficiency after 48 h) or HeLa cells (60-70% after 24 h), respectively. For stable transfections, B9 cells were Figure 7 Model for the role of specific complex II inhibition for apoptosis induction by various pro-apoptotic compounds. (a) In healthy cells, complex II serves to funnel electrons derived from the Krebs cycle to the respiratory chain. SDHA-mediated oxidation of succinate to fumarate by the succinate dehydrogenase activity (SDH), as part of the Krebs cycle, provides electrons to complex II. They are transferred to the iron-sulfur centres of the SDHB subunit and finally to the CoQ reduction site at the interface between SDHC and SDHD, the two transmembrane subunits of complex II. The succinate CoQ oxidoreductase (SQR) reaction comprises, in addition, the transfer of the electrons to CoQ. (b) Pro-apoptotic compounds, such as various anticancer drugs, FasL, or TNF-a, induce intracellular (pH i ) and mitochondrial (pH M ) acidification. These pH changes lead to the dissociation of the SDHA/B subunits from complex II and finally to the partial inhibition of the SQR activity without any impairment of the SDH reaction. This specific inhibition leads to complex II uncoupling, superoxide production, and apoptosis selected at 3 weeks with 800 mg/ml G418. Previously described expression vectors for mitochondrial MnSOD, catalase, luciferase, NHE1, and wt SDHC were used. 16, 42, 43 Apoptosis and necrosis quantification. Apoptotic cells were quantified using flow cytometry by determining the percentage of cells with subG1-DNA content. This subG1 population was analysed after cell permeabilisation and subsequent PI staining, as previously described. 16, 44 For some experiments, apoptosis and necrosis were quantified at the same time on non-permeabilised cells by flow cytometry with an Alexa Fluor 488-conjugated AV and PI kit, according to the manufacturer's protocol (Invitrogen, Paisley, UK). Cells with compromised membrane integrity were also specifically quantified by flow cytometry using 7-AAD, according to the supplier's protocol (Invitrogen).
ROS detection. The ROS-sensitive probe DHE and its mitochondria-targeted derivative MitoSOX were used, according to previously published protocols. 33, 45 Briefly, cells were treated with the indicated conditions, harvested, and washed in phosphate-buffered saline (PBS) before the addition of 150 ml of a PBS solution containing DHE (5 mM) or MitoSOX (5 mM). Cells were incubated at 371C for 25 or 10 min, respectively, and then washed and resuspended in PBS. Fluorescence was measured by flow cytometry using a FACScalibur (FL2-H channel), and a minimum of 4000 cells were counted for each sample.
Total RNA isolation and reverse transcriptase PCR assay. Total RNAs were extracted with TRIzol and subjected to reverse transcriptase PCR. 18 The primers used are described in Supplementary Table 3 .
Mitochondria isolation. Mitochondria were isolated with established protocols, 18 resuspended in lysis buffer, and kept at À801C.
Complex II activity assays. Complex II activities were measured by spectrophotometric tests on 10 mg of mitochondria, using the SDH (PMS-mediated DCPIP reduction) and the SQR assay (CoQ-dependent reduction of DCPIP). 16, 18 For measurements at pH 6.7 and 7.3, we used the normal phosphate buffer with different ratios K 2 HPO 4 /KH 2 PO 4 to obtain the acidic or neutral pH (Gomorri Buffers tables).
Western blotting. For each sample, mitochondria (30 mg) were separated in a 14% SDS polyacrylamide gel electrophoresis and electroblotted onto nitrocellulose membranes (BioRad, Hemel Hempstead, UK), which were processed as described. 18 Goat polyclonal Abs against SDHB and SDHD were purchased from Santa Cruz Biotechnology (Heidelberg, Germany), mouse mAbs against SDHA and COX IV from Abcam (Cambridge, UK), and mouse mAbs against Cyt c and SDHC from BD Pharmingen (Oxford, UK) and Abnova (Stratech Scientific, Newmarket, UK), respectively.
Measurements of pH i . The pH i of HeLa cells was monitored using the pH-sensitive fluorescent probe carboxy-SNARF-1. After a 7-h treatment, cells were collected and loaded with SNARF (5 mM) for 30 min at 371C, in a cell suspension buffer (CSB). The mean fluorescence intensity (MFI) of 10 000 cells was determined by flow cytometry (l ex. ¼ 488 nm, l em. ¼ FL2-H 580 nm and FL3-H 640 nm). The emission ratio 640/580 was converted into pH value by using the calibration curve obtained in situ on control cells exposed to calibration buffers containing 10 mM nigericin. 43 Mitochondrial matrix pH. The pH M was monitored using two mitochondrial targeted plasmids (Aequotech, Ferrara, Italy): mt-EYFP (pH-sensitive enhanced yellow fluorescent protein) and mt-dsRed (pH-insensitive red fluorescent protein) used as a transfection rate control. 46 HeLa cells were co-transfected overnight with these two plasmids. After 24 h, cells were treated for 7 h with the different proapoptotic agents. Cells were then collected, re-suspended in CSB, and analysed by flow cytometry. MFI was determined on 10 000 cells (l ex. ¼ 488 nm, l em. EYFP ¼ FL1-H 530 nm and l em. DsRed ¼ FH3-H 640 nm). A standard curve was generated in situ on control cells exposed to calibration buffers containing ionophores nigericin and monensin, allowing the conversion of the MFI ratio 530/ 640 into pH value. CCCP, a mitochondrial protonophore, was used as control for pH M acidification. 46 Blue native gel PAGE. For in vitro pH experiments, fresh mitochondria isolated using a commercial isolation kit (Pierce, Thermo Fisher Scientific, Cramlington, UK) were incubated in the indicated phosphate buffer (see complex II activity assays). Mitochondrial complex II was gently solubilised in a 50 mM Bis-Tris buffer containing 1.25% n-dodecyl-D-maltoside and 750 mM 6-aminocaproic acid on ice for 30 min and the supernatant collected after centrifugation (20 000 Â g, 30 min). For experiments on transfected and/or treated cells, HeLa cells were lysed using 5% n-dodecyl-D-maltoside in PBS. Samples were incubated on ice for 30 min and centrifuged (17 000 Â g, 30 min). For both experiments, Native Sample buffer (Bio-Rad), supplemented with 1.25% (final concentration) Coomassie Brilliant Blue G solution (5% Coomassie Brilliant Blue G, 750 mM 6-aminocaproic acid and 50 mM Bis-Tris), was added to the supernatants. Proteins were loaded on a Ready-Gel 4-15% (Bio-Rad) for Blue Native Page and western blot was performed according to established protocols. Blots were probed with an SDHA antibody (Invitrogen).
Statistical analysis. The results are presented as means ± S.D. of at least three independent experiments. Significant differences (Po0.05) were evaluated with the Student t-test. Western blots and PCR results are representative of at least three different experiments.
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